ArticleFrontiers in pediatrics2025
Outcomes of liver transplantation of hepatoblastoma: single-center data in mainland China.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Liver transplantation for pediatric liver tumors: a case report of hepatic angiosarcoma with literature review.Quantitative imaging in medicine and surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: HB is the most common liver malignancy in children. Giving the rarity of the research reporting outcomes of LT for HB in China, updated long-term data are needed. The primary objective was to evaluate the outcomes of liver transplantation in HB. The secondary objective was to assess the clinical parameters that influence the outcomes of liver transplantation in HB. Methods: We retrospectively analyzed the dataset of a single-center cohort from RJ-SJTUM. Outcomes were OS and PFS. Cox proportional hazard models were used to estimate mortality adjusted HRs with 95% CIs. Results: RJ-SJTUM has accounted for 68.5% of the total cases in China since 2019. The 5-year PFS and OS rates were 63.6% and 84.6% respectively. AFP ≥13,686.5 ng/ml before LT was an independent risk factor for PFS ( Conclusion: LT achieved favorable outcomes for patients with locally advanced hepatoblastoma. This study suggests that a judicious patient selection to exclude patients with high-risk predictors, as well as standardized postoperative management is critical in this process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.